Kun for helsepersonell
In patients who achieved at least a JIA ACR30 response by the end of the open-label phase
Key secondary endpoint2
I den åpne fasen av studie JIA-I oppnådde 45 % av pasientene med JIA som fikk XELJANZ JIA ACR30 ved uke 21-3
A 44-week, 2-part study (consisting of an 18-week, open-label, run-in phase, followed by a 26-week double-blind, placebo-controlled, randomized phase) in patients 2 to
<18 years of age with pJIA (including RF positive or RF negative polyarthritis, extended oligoarthritis, systemic JIA with active arthritis and no current systemic symptoms) and patients 2 to <18 with jPsA and ERA. However, the pJIA efficacy population only includes the subgroups with either RF positive or RF negative polyarthritis or extended oligoarthritis; inconclusive results have been seen in the subgroup of patients with systemic JIA with active arthritis and no current systemic symptoms. Patients with juvenile PsA are included as separate efficacy subgroup. ERA patients are not included in the efficacy analysis.1,2
A total of 225 patients were enrolled in the 18-week open-label run-in phase and received XELJANZ/XELJANZ Oral Solution dosed at 5 mg BID or body weight-based equivalent BID. Only patients who achieved at least a JIA ACR30 response at the end of the run-in phase (week 18) were randomized (1:1) to the double-blind phase. 173 patients (77%) met this criterion and were randomized into the double-blind phase to either XELJANZ/XELJANZ Oral Solution dosed at 5 mg BID or body weight-based equivalent BID (n=88) or placebo (n=85) for 26 weeks. Treatment with MTX was permitted but was not required during the study.1
The primary endpoint was JIA flare rate by week 44. Flare is defined as a worsening of ≥30% in ≥3 of the 6 variables of the JIA core set, with ≤1 variable improving by ≥30%.2
Lær mer om sikkerhetsprofilen til XELJANZ
Les om fleksibiliteten i doseringsstyrke og administrasjonsform
Finn ut mer om erfaringer ved bruk av XELJANZ innen RA, PsA, AS, UC og JIA
Pfizer AS, Org.nr 915 213 596
Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo
Tlf.: +47 67 52 61 00
PP-BCP-NOR-0001 juni 2023
Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.